Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 6 · 85.7%High 0 · 0%

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1.18 [0.88, 1.58]
1 study · 225 participants
Moderate

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + 5FC (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1.27 [0.94, 1.72]
1 study · 226 participants
Moderate

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + FLU probably leads to higher mortality: 10 weeks compared with two weeks of 5FC + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1.39 [1.07, 1.8]
1 study · 336 participants
Moderate

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + 5FC + FLU showed no clear difference in mortality: 10 weeks compared with one week of AmBd + FLU (low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.86 [0.35, 2.1]
1 study · 40 participants
Low

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + 5FC probably leads to lower mortality: 10 weeks compared with one week of AmBd + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.49 [0.34, 0.72]
1 study · 224 participants
Moderate

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + 5FC probably leads to lower mortality: 10 weeks compared with two weeks of AmBd + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.58 [0.39, 0.86]
1 study · 227 participants
Moderate

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + 5FC probably leads to lower mortality: 10 weeks compared with two weeks of 5FC + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.68 [0.47, 0.99]
1 study · 338 participants
Moderate